Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $14.81
  • 50 Day Moving Average: $16.42
  • 200 Day Moving Average: $18.60
  • 52-Week Range: $10.50 - $21.75
  • Trailing P/E Ratio: 33.17
  • Foreward P/E Ratio: 29.78
  • P/E Growth: 1.26
  • Market Cap: $699.09M
  • Outstanding Shares: 46,023,000
  • Beta: 1.74
Profitability:
  • Net Margins: 7.75%
  • Return on Equity: 6.79%
  • Return on Assets: 5.14%
Debt:
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 3.13%
  • Quick Ratio: 1.64%
Additional Links:
Companies Related to Amphastar Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Amphastar Pharmaceuticals (NASDAQ:AMPH) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $21.67 (42.64% upside)

Analysts' Ratings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Show:
DateFirmActionRatingPrice TargetDetails
12/21/2016Wells Fargo & CoReiterated RatingOutperform$22.00 -> $29.00View Rating Details
11/9/2016Jefferies Group LLCSet Price TargetBuy$19.00 -> $21.00View Rating Details
9/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00 -> $23.00View Rating Details
8/9/2016BMO Capital MarketsReiterated RatingHold$17.00View Rating Details
8/9/2016Needham & Company LLCBoost Price TargetBuy$20.00 -> $22.00View Rating Details
3/15/2016Raymond James Financial, Inc.Lower Price Target$23.00 -> $18.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/8/2016Q3$0.03$0.14$65.12 million$64.20 millionViewListenView Earnings Details
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.08)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.07)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014($0.11)$0.02ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Current Year EPS Consensus Estimate: $0.47 EPS
Next Year EPS Consensus Estimate: $0.51 EPS

Dividends

Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Ownership Percentage: 29.30%
Institutional Ownership Percentage: 49.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Floyd F PetersenDirectorSell400$18.61$7,444.00View SEC Filing  
12/15/2016Diane G GerstEVPSell2,940$20.51$60,299.40View SEC Filing  
12/5/2016Rong ZhouEVPSell61$20.70$1,262.70View SEC Filing  
12/1/2016Floyd F PetersenDirectorSell400$20.26$8,104.00View SEC Filing  
11/28/2016Jason B ShandellInsiderSell26,335$20.48$539,340.80View SEC Filing  
11/15/2016Howard LeeDirectorSell37,994$20.65$784,576.10View SEC Filing  
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.00View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.97View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.00View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateHeadline
News IconConsensus Price Target Updates for Internap Corporation (NASDAQ:INAP) Amphastar Pharmaceuticals, Inc. (NASDAQ ... - Davidson Register (NASDAQ:AMPH)
davidsonregister.com - February 25 at 3:28 PM
News IconInvestor Scope: Taking a Closer Look at Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Midway Monitor (NASDAQ:AMPH)
midwaymonitor.com - February 24 at 8:43 PM
News IconReviewing the Numbers for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Searcy News (NASDAQ:AMPH)
searcysentinel.com - February 24 at 3:43 PM
News IconAG Healey Reminds First Responders of Statewide Naloxone Fund Following Uptick in Cost for Overdose Drug Evzio (NASDAQ:AMPH)
www.mass.gov - February 24 at 11:46 AM
News IconFDA Wants More Info from Amphastar for New Opioid Nasal Treatment - Pharmaceutical Processing (NASDAQ:AMPH)
www.pharmpro.com - February 23 at 3:32 PM
News IconAnalysts Peer Into Their Crystal Balls For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH): Where Is It headed? - Winfield Review (NASDAQ:AMPH)
winfieldreview.com - February 23 at 3:32 PM
globenewswire.com logoAmphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose - GlobeNewswire (press release) (NASDAQ:AMPH)
globenewswire.com - February 22 at 3:32 PM
News IconAre Insiders Selling Their Positions in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)? - Winfield Review (NASDAQ:AMPH)
winfieldreview.com - February 22 at 3:32 PM
News IconMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) missed earnings on 6 occasions (NASDAQ:AMPH)
www.graffiotech.com - February 22 at 11:32 AM
reuters.com logoFDA rejects Amphastar's nasal opioid overdose treatment (NASDAQ:AMPH)
www.reuters.com - February 22 at 11:32 AM
capitalcube.com logoAmphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : February 22, 2017 (NASDAQ:AMPH)
www.capitalcube.com - February 22 at 11:32 AM
benzinga.com logo20 Stocks Moving In Tuesday's Pre-Market Session - Benzinga (NASDAQ:AMPH)
www.benzinga.com - February 21 at 3:47 PM
News IconIs there Upside to Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock? - Rockville Register (NASDAQ:AMPH)
rockvilleregister.com - February 21 at 3:47 PM
schaeffersresearch.com logoCidara Therapeutics, Momenta Pharmaceuticals, Amphastar Pharmaceuticals Stocks Moving Today - Schaeffers Research (blog) (NASDAQ:AMPH)
www.schaeffersresearch.com - February 21 at 3:47 PM
marketwatch.com logoAmphastar Pharma stock plummets 16% after FDA fails to approve nasal spray for opioid overdoses - MarketWatch (NASDAQ:AMPH)
www.marketwatch.com - February 21 at 3:47 PM
marketwatch.com logoAmphastar Pharma stock plummets 16% after FDA fails to approve nasal spray for opioid overdoses (NASDAQ:AMPH)
www.marketwatch.com - February 21 at 3:47 PM
investopedia.com logoFDA Rejects Amphastar's Nasal Opioid Overdose Drug (NASDAQ:AMPH)
www.investopedia.com - February 21 at 3:47 PM
finance.yahoo.com logoFDA rejects Amphastar's nasal opioid overdose treatment - Yahoo Finance (NASDAQ:AMPH)
finance.yahoo.com - February 21 at 7:27 AM
News IconAmphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose - EconoTimes (NASDAQ:AMPH)
www.econotimes.com - February 21 at 7:27 AM
finance.yahoo.com logoAmphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose (NASDAQ:AMPH)
finance.yahoo.com - February 21 at 7:27 AM
finance.yahoo.com logo6:02 am Amphastar Pharmaceuticals receives a CRL for its NDA for for Naloxone Hydrochloride 2mg/0.5mL Nasal Spray; CRL identifies issues including user human factors study, device evaluation, and other items that need to be addressed before (NASDAQ:AMPH)
finance.yahoo.com - February 21 at 7:27 AM
finance.yahoo.com logoFDA rejects Amphastar's nasal version of opioid overdose treatment (NASDAQ:AMPH)
finance.yahoo.com - February 21 at 7:27 AM
News IconWatching the Numbers for Amphastar Pharmaceuticals Inc. (AMPH) - Baldwin Journal (NASDAQ:AMPH)
baldwinjournal.com - February 18 at 9:38 AM
News IconShedding Light On Growth Forecasts For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Rockville Register (NASDAQ:AMPH)
rockvilleregister.com - February 18 at 9:38 AM
News IconThe Bears And Bulls Square Off On Amphastar Pharmaceuticals, Inc. (AMPH) - NY Stock News (NASDAQ:AMPH)
nystocknews.com - February 18 at 9:38 AM
News IconBeyond Pay-for-Delay: Three Pharma Antitrust Cases To Watch In 2017 (NASDAQ:AMPH)
www.lexology.com - February 17 at 6:35 PM
News IconIs The Sell-Side Predicting That Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Move Higher? - Winfield Review (NASDAQ:AMPH)
winfieldreview.com - February 16 at 3:34 PM
News IconAre Analysts Optimistic About Where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is Heading? - Winfield Review (NASDAQ:AMPH)
winfieldreview.com - February 16 at 8:25 AM
News IconWhere to From Here, Analysts Weigh in on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Rockville Register (NASDAQ:AMPH)
rockvilleregister.com - February 13 at 8:58 PM
law360.com logo1st Circ. Gauges Antitrust Immunity In Enoxaparin Row (NASDAQ:AMPH)
www.law360.com - February 11 at 2:02 AM
News IconInvestor Scope: Taking a Closer Look at Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Sherwood Daily (NASDAQ:AMPH)
sherwooddaily.com - February 9 at 3:33 PM
law360.com logo1st Circ. To Size Up Antitrust Shield In Enoxaparin Row (NASDAQ:AMPH)
www.law360.com - February 9 at 1:47 AM
law360.com logo1st Circ. To Size Up Antitrust Shield In Enoxaparin Row - Law360 (subscription) (NASDAQ:AMPH)
www.law360.com - February 8 at 8:45 PM
News IconShares Making an Appearance on Today's Most Volatile List: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Davidson Register (NASDAQ:AMPH)
davidsonregister.com - February 6 at 3:33 PM
finance.yahoo.com logoLifshitz & Miller Law Firm Announces Investigation of Ally Financial Inc., Amphastar Pharmaceuticals, Inc., Lannett Company, Inc., Live Ventures Incorporated, MiMedx Group, Inc., Seattle Genetics, Inc., Teligent, Inc., TerraVia Holdings, In (NASDAQ:AMPH)
finance.yahoo.com - February 1 at 8:39 PM
News IconShows Sign of Reversal, Multiple Top Pattern Forms for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Wall Street Beacon (NASDAQ:AMPH)
wsbeacon.com - February 1 at 3:38 PM
News IconAmphastar Pharmaceuticals Inc (AMPH) Formed a Multiple Top Chart Pattern, Could Be One of The Best Performers ... - The Randolph Guide (NASDAQ:AMPH)
randolphguide.com - January 30 at 3:56 PM
News IconTechnical Trading: Focus on Shares of Amphastar Pharmaceuticals Inc. (AMPH) - Market Point (NASDAQ:AMPH)
mtptnews.com - January 30 at 3:56 PM
News IconEarnings Analysis & Update for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)? - Aiken Advocate (NASDAQ:AMPH)
aikenadvocate.com - January 26 at 8:50 PM
News IconRelative Strength Index Check on Amphastar Pharmaceuticals Inc. (AMPH) - Market Point (NASDAQ:AMPH)
mtptnews.com - January 26 at 3:49 PM
News IconTrading Watch: Checking in on Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - The Tribune (NASDAQ:AMPH)
lakecitytribune.com - January 25 at 8:37 PM
openpr.com logoAmphastar Pharmaceuticals Inc (NASDAQ:AMPH) Investor Investigation over possible Violations of Securities Laws (NASDAQ:AMPH)
www.openpr.com - January 25 at 3:36 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Wall Street Beacon (NASDAQ:AMPH)
wsbeacon.com - January 21 at 2:31 AM
News IconWhat is the Street Saying About Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)? - Aiken Advocate (NASDAQ:AMPH)
aikenadvocate.com - January 19 at 9:02 PM
News IconInvestigation for Investors in NASDAQ:AMPH shares over potential Securities Laws Violations by Amphastar Pharmaceuticals Inc announced (NASDAQ:AMPH)
www.groundreport.com - January 17 at 10:04 AM
News IconWhat are the Technical Charts Saying About Amphastar Pharmaceuticals Inc. (AMPH) - Springdale Times (NASDAQ:AMPH)
springdaletimes.com - January 16 at 8:31 PM
News IconWill The Needle Move For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:AMPH)
wsbeacon.com - January 16 at 8:31 PM
News IconAmphastar Pharmaceuticals Inc AMPH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:AMPH)
www.bioportfolio.com - January 14 at 2:01 AM
law360.com logoConsumer Orgs Ask 1st Circ. To Ax Momenta Antitrust Shield (NASDAQ:AMPH)
www.law360.com - January 11 at 8:48 PM
finance.yahoo.com logo6 Major FDA Decisions and Biopharma Catalysts Coming in January and February (NASDAQ:AMPH)
finance.yahoo.com - January 6 at 3:37 PM

Social

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Where is Amphastar Pharmaceuticals' stock going? Where will Amphastar Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1 year price targets for Amphastar Pharmaceuticals' stock. Their predictions range from $17.00 to $29.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $21.67 in the next year.

When will Amphastar Pharmaceuticals announce their earnings?

Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (2.92%), FMR LLC (2.86%), State Street Corp (2.08%), Dimensional Fund Advisors LP (1.74%), Russell Investments Group Ltd. (0.69%) and AQR Capital Management LLC (0.20%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Marilyn J Purchase, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters.

Who sold Amphastar Pharmaceuticals stock? Who is selling Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bogle Investment Management L P DE, Federated Investors Inc. PA, Menta Capital LLC, Guggenheim Capital LLC, Two Sigma Investments LP, State Board of Administration of Florida Retirement System and AQR Capital Management LLC. Company insiders that have sold Amphastar Pharmaceuticals stock in the last year include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters.

Who bought Amphastar Pharmaceuticals stock? Who is buying Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., Oxford Asset Management, State Street Corp, GSA Capital Partners LLP, Trexquant Investment LP, New York State Teachers Retirement System and Comerica Bank.

How do I buy Amphastar Pharmaceuticals stock?

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amphastar Pharmaceuticals stock cost?

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $15.19.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings History Chart

Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Dividend History Chart

Dividend Payments by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Last Updated on 2/25/2017 by MarketBeat.com Staff